Sign in

Trial result ·

Efficacy and safety of cyclosporine plus luspatercept versus cyclosporine in newly diagnosed non-transfusion-dependent non-severe aplastic anemia: A prospective randomized trial.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This study tested a drug mix for a blood disease called aplastic anemia. All people had just been found to have the disease. Their disease was not severe, and they did not need blood transfusions. Each person was put by chance into a group. One group took cyclosporine alone. The other group took cyclosporine plus a drug called luspatercept. In all, 58 people were in the final results, 29 per group.

What they found

The typical follow-up was 12 months in each group. At 3 months, more people on the mix had responded to treatment. This was also true at 6 months. At the end of follow-up, the gap between groups was not clear in the tests. People on the mix also responded sooner than people on cyclosporine alone. An extra check, planned after the fact, split people by age. Under 60, the groups did not differ clearly. In people 60 or older, the mix did better at 3 and 6 months.

What it means for patients

The authors say the mix led to more responses than cyclosporine alone. People also responded faster with the mix. The authors say its safety was acceptable. They say the gain was largest in older people.

Why it is not certain yet

The abstract does not give details on side effects. At the end of follow-up, the gain was no longer clear. For some people, follow-up lasted only 6 or 7 months. The age results came from a check planned after the trial. Such checks can show results that happen by chance.

The registered trial

The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.

Source

Efficacy and safety of cyclosporine plus luspatercept versus cyclosporine in newly diagnosed non-transfusion-dependent non-severe aplastic anemia: A prospective randomized trial.

PubMed · PMID 42057135

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Aplastic anaemia publications